Withdrawal of Two Proposed Rules, 79400 [2016-27329]
Download as PDF
<![CDATA[
79400
Federal Register / Vol. 81, No. 219 / Monday, November 14, 2016 / Proposed Rules
(o) Related Information
(1) For more information about this AD,
contact Wayne Lockett, Aerospace Engineer,
Airframe Branch, ANM–120S, FAA, Seattle
ACO, 1601 Lind Avenue SW., Renton, WA
98057–3356; phone: 425–917–6447; fax: 425–
917–6590; email: wayne.lockett@faa.gov.
(2) For service information identified in
this AD, contact Boeing Commercial
Airplanes, Attention: Data & Services
Management, P.O. Box 3707, MC 2H–65,
Seattle, WA 98124–2207; telephone 206–
544–5000, extension 1; fax 206–766–5680;
Internet https://www.myboeingfleet.com. You
may view this referenced service information
at the FAA, Transport Airplane Directorate,
1601 Lind Avenue SW., Renton, Washington.
For information on the availability of this
material at the FAA, call 425–227–1221.
Issued in Renton, Washington, on
September 12, 2016.
Michael Kaszycki,
Acting Manager, Transport Airplane
Directorate, Aircraft Certification Service.
[FR Doc. 2016–22699 Filed 11–10–16; 8:45 am]
BILLING CODE 4910–13–P
21 CFR Chapter 1
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 3326, Silver Spring,
MD 20993–0002, 301–796–9135, email:
Lisa.Helmanis.@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
[Docket No. FDA–2008–N–0622]
I. Background
Withdrawal of Two Proposed Rules
In 1990, FDA began a process of
periodically conducting comprehensive
reviews of its regulation process,
including reviewing the backlog of
notices of proposed rulemakings that
were never finalized. As FDA removed
many proposed rules that had not been
finalized, the Agency was able to clean
out the backlog and implement a
process of reviewing these proposed
rules every 5 years. In the Federal
Register of December 12, 2008 (73 FR
75625), FDA withdrew four proposed
rules that were more than 5 years old
that it did not intend to finalize.
Recently, FDA has conducted a
review of proposed rules that are more
than 5 years old, and is announcing the
withdrawal the following two proposed
rules:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of withdrawal.
The Food and Drug
Administration (FDA) is announcing the
withdrawal of two proposed rules that
published in the Federal Register more
than 5 years ago. These proposed rules
are no longer considered viable
candidates for final action. FDA is
taking this action because these
proposed rules are out of date.
DATES: The proposed rules are
withdrawn on November 14, 2016.
FOR FURTHER INFORMATION CONTACT: Lisa
M. Helmanis, Regulations Policy and
Management Staff, Office of the
SUMMARY:
Publication date and
Docket No.
Reason for withdrawal
1 ...................
Availability for Public Disclosure and Submission
to FDA for Public Disclosure of Certain Data
and Information Related to Human Gene Therapy or Xenotransplantation.
1/18/2001, 00N–0989 ....
2 ...................
Lhorne on DSK30JT082PROD with PROPOSALS
Title of proposed rule
Crabmeat; Amendment of Common or Usual
Name Regulation.
4/23/1998, 94P–0043 ....
FDA has reconsidered our position on this issue
and deemed our concerns from 2001 outdated.
We will continue to assess whether rulemaking
in this area is necessary, and if so, we will proceed with a new proposed rule.
This proposed rule is obsolete because FDA has
created a new process that allows for routine
updates to the seafood names without going
through notice and comment rulemaking. See
FDA’s Guide to Acceptable Market Names for
Seafood Sold in Interstate Commerce.
The withdrawal of these proposals
identified in this document does not
preclude the Agency from reinstituting
rulemaking concerning the issues
addressed in the proposals listed in the
chart. Should we decide to undertake
such rulemakings in the future, we will
re-propose the actions and provide new
opportunities for comment.
Furthermore, this notice is only
intended to address the specific actions
identified in this document, and not any
other pending proposals that the Agency
has issued or is considering. The
Agency notes that withdrawal of a
proposal does not necessarily mean that
the preamble statement of the proposal
no longer reflects the current position of
FDA on the matter addressed. You may
wish to review the Agency’s Web site
(https://www.fda.gov) for any current
guidance on the matter.
VerDate Sep<11>2014
15:04 Nov 10, 2016
Jkt 241001
Dated: November 8, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–27329 Filed 11–10–16; 8:45 am]
BILLING CODE 4164–01–P
NATIONAL MEDIATION BOARD
29 CFR Part 1208
[Docket No. C–7156]
RIN 3140–AA00
Access to Information
The National Mediation
Board (NMB or Board) proposes to
revise its Freedom of Information Act
(FOIA) regulations in order to
implement the FOIA Improvement Act
PO 00000
Frm 00007
Fmt 4702
Sfmt 4702
Submit comments on or before
January 13, 2017. The NMB will hold a
public hearing on Thursday, December
8, 2016. Submit requests to speak at the
hearing until 4 p.m. EST on Thursday,
December 1, 2016.
DATES:
You may submit comments
by any of the methods listed below.
Please submit requests to speak and
materials for the public hearing only to
the NMB’s physical or email address.
Clearly identify all submissions by
Docket Number C–7156.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
ADDRESSES:
National Mediation Board.
ACTION: Proposed rule with request for
comments; notice of hearing.
AGENCY:
SUMMARY:
of 2016 and to amend its regulations
regarding responding to subpoenas. The
NMB also proposes to update these
regulations where needed in accordance
with Department of Justice guidance,
Executive Order 12,600, and changes in
Agency practice and procedure.
E:\FR\FM\14NOP1.SGM
14NOP1
]]>Agencies
[Federal Register Volume 81, Number 219 (Monday, November 14, 2016)]
[Proposed Rules]
[Page 79400]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-27329]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Chapter 1
[Docket No. FDA-2008-N-0622]
Withdrawal of Two Proposed Rules
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
withdrawal of two proposed rules that published in the Federal Register
more than 5 years ago. These proposed rules are no longer considered
viable candidates for final action. FDA is taking this action because
these proposed rules are out of date.
DATES: The proposed rules are withdrawn on November 14, 2016.
FOR FURTHER INFORMATION CONTACT: Lisa M. Helmanis, Regulations Policy
and Management Staff, Office of the Commissioner, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3326, Silver
Spring, MD 20993-0002, 301-796-9135, email: Lisa.Helmanis.@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In 1990, FDA began a process of periodically conducting
comprehensive reviews of its regulation process, including reviewing
the backlog of notices of proposed rulemakings that were never
finalized. As FDA removed many proposed rules that had not been
finalized, the Agency was able to clean out the backlog and implement a
process of reviewing these proposed rules every 5 years. In the Federal
Register of December 12, 2008 (73 FR 75625), FDA withdrew four proposed
rules that were more than 5 years old that it did not intend to
finalize.
Recently, FDA has conducted a review of proposed rules that are
more than 5 years old, and is announcing the withdrawal the following
two proposed rules:
----------------------------------------------------------------------------------------------------------------
Publication date and
Title of proposed rule Docket No. Reason for withdrawal
----------------------------------------------------------------------------------------------------------------
1........................ Availability for Public 1/18/2001, 00N-0989..... FDA has reconsidered our
Disclosure and Submission to position on this issue and
FDA for Public Disclosure of deemed our concerns from
Certain Data and Information 2001 outdated. We will
Related to Human Gene continue to assess whether
Therapy or rulemaking in this area is
Xenotransplantation. necessary, and if so, we
will proceed with a new
proposed rule.
2........................ Crabmeat; Amendment of Common 4/23/1998, 94P-0043..... This proposed rule is
or Usual Name Regulation. obsolete because FDA has
created a new process that
allows for routine updates
to the seafood names
without going through
notice and comment
rulemaking. See FDA's Guide
to Acceptable Market Names
for Seafood Sold in
Interstate Commerce.
----------------------------------------------------------------------------------------------------------------
The withdrawal of these proposals identified in this document does
not preclude the Agency from reinstituting rulemaking concerning the
issues addressed in the proposals listed in the chart. Should we decide
to undertake such rulemakings in the future, we will re-propose the
actions and provide new opportunities for comment. Furthermore, this
notice is only intended to address the specific actions identified in
this document, and not any other pending proposals that the Agency has
issued or is considering. The Agency notes that withdrawal of a
proposal does not necessarily mean that the preamble statement of the
proposal no longer reflects the current position of FDA on the matter
addressed. You may wish to review the Agency's Web site (https://www.fda.gov) for any current guidance on the matter.
Dated: November 8, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-27329 Filed 11-10-16; 8:45 am]
BILLING CODE 4164-01-P
